HGF/c-Met raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
=== Final tour and death in New York === Thomas left Laugharne on 9 October 1953 on the first leg of his fourth trip to America. He called on his mother, Florence, to say goodbye: "He always felt that he had to get out from this country because of his chest being so bad." Thomas had suffered from chest problems for most of his life, though they began in earnest soon after he moved in May 1949 to the Boat House at Laugharne—the "bronchial heronry", as he called it. Within weeks of moving in, he visited a local doctor, who prescribed medicine for both his chest and throat. While waiting in London before his flight, Thomas stayed with the comedian Harry Locke and worked on Under Milk Wood. Locke noted that Thomas was having trouble with his chest, "terrible" coughing fits that made him go purple in the face. He was also using an inhaler to help his breathing. There were reports, too, that Thomas was also having blackouts. His visit to the BBC producer Philip Burton, a few days before he left for New York, was interrupted by a blackout. On his last night in London, he had another in the company of his fellow poet Louis MacNeice. Thomas arrived in New York on 20 October 1953 to undertake further performances of Under Milk Wood, organised by John Brinnin, his American agent and Director of the Poetry Centre. Brinnin did not travel to New York but remained in Boston to write. He handed responsibility to his assistant, Liz Reitell. She met Thomas at Idlewild Airport and was shocked at his appearance.
=== Built under license === Focke-Wulf C.19 – license-built (autogyro)– licence-built version of the Cierva C.19, with Siemens Sh 14 engine. (one prototype, converted from Cierva C.19 Mk.IV) Focke-Wulf C.30 Heuschrecke (Grasshopper) – licence-built version of the Cierva C.30, with Siemens Sh 14 engine. Focke-Wulf FWP.149D – license-built Piaggio P.149
==== Granuloma ==== Drug-induced hepatic granulomas are usually associated with granulomas in other tissues and patients typically have features of systemic vasculitis and hypersensitivity. More than 50 drugs have been implicated.
10-second substitutions: Players being substituted had ten seconds to exit the field; otherwise, the substitute had to wait for one minute before entering the match. 5-second restarts: A visual 5-second countdown was shown by the referee for throw-ins and goal kicks in situations of time-wasting. If the ball was not put into play in time, a restart was awarded to the opposing team; a corner kick was awarded if the infraction occurred with a goal kick. Medical treatment: Any outfield player who received medical attention on the field had to leave the field and wait for 1 minute before returning to play. Expanded video assistant referee (VAR): The VAR could review and overturn wrongly awarded corner kicks, certain attacking fouls, and clear mistakes on red cards given from a second yellow card. Mouth-covering red cards: To stop confrontational or insulting behavior which was concealed to avoid lip-reading, any player who covered his mouth with his hand, arm, or shirt while confronting an opponent was sent off. Player leaving the field in protest: Players or officials who left the field in protest were sent off. Another change was the tiebreaker formula used when two or more teams finish the group stage with an equal number of points. The first tiebreaker criteria was the number of points earned in head-to-head matches between the tied teams, not the goal difference among all matches.
Sources: en.wikipedia.org
=== 1990–1992: Facelift and Sap === Alice in Chains soon became a top priority of the label, which released the band's first official recording in July 1990, a promotional EP called We Die Young. The EP's lead single, "We Die Young", became a hit on metal radio. After its success, the label rushed Alice in Chains' debut album into production with producer Dave Jerden. Cantrell stated the album was intended to have a "moody aura" that was a "direct result of the brooding atmosphere and feel of Seattle." The resulting album, Facelift, was released on August 21, 1990, peaking at number 42 in mid-1991 on the Billboard 200 chart. Facelift was not an instant success, selling under 40,000 copies in the first six months of release, until MTV added "Man in the Box" to regular daytime rotation. The single hit number 18 on the Mainstream rock charts, with the album's follow up single, "Sea of Sorrow", reaching number 27, and in six weeks Facelift sold 400,000 copies in the US. The album was a critical success, with Steve Huey of AllMusic citing Facelift as "one of the most important records in establishing an audience for grunge and alternative rock among hard rock and heavy metal listeners." Sammy Hagar claimed he invited the band to tour with Van Halen after he saw the music video for "Man In The Box" on MTV.
Upon hearing of the assassination of socialist candidate Jorge Eliécer Gaitán, many poor workers saw the death of Gaitán as a political assassination orchestrated by the rich. Workers began rioting and destroying the Colombian capital of Bogotá, leading to the death of 4,000 people. When news of the death of Gaitán reached the countryside, the local militias were furious and immediately started a civil war, known as La Violencia. Joined by fellow leftists, a brutal war was fought for over 10 years, leading to the death of 200,000 people and the destruction of much of the country, resulting in a peace settlement and the changing of power from the Colombian Conservative Party to the Colombian Liberal Party and the Colombian Communist Party in 1958. As La Violencia wound down, most self-defense and guerrilla units composed of Liberal Party supporters were demobilized. At the same time, some former liberals and active communist groups continued operating in several rural enclaves. One of the Liberal bands was a group known as the "Fuerzas Armadas Revolucionarias de Colombia" (Revolutionary Armed Forces of Colombia), or FARC, formed by Pedro Antonio Marín in 1964. The FARC was founded out of fighters who were unhappy with the peace settlement. The goal of the FARC, among other things, was land redistribution that would benefit poor peasant farmers like Marín, along with the desire to establish a socialist state. In 1958, an exclusively bipartisan political alternation system, known as the National Front, resulted from an agreement between the Liberal and Conservative parties.
== History == Crocodile oil was used by traditional practitioners for centuries in treatment of ailments, skin conditions, and illnesses such as cancer. In Ancient Egyptian medicine, crocodile oil was used in a liniment to stimulate the growth of hair, to treat bald patches also called alopecia as well as prevent grey hair growth. Crocodile oil was recognised by the Ancient Egyptians to treat burns when combined with other components such as Egyptian goat fat and lion fat. Crocodile oil was also used by the Egyptians to help with trembling in limbs when smeared with other components including honey and olive oil. The Papyrus Ebers mentions Egyptians medicine recommends the creation of a vaginal contraceptive solution composed of crocodile oil, gum acacia or honey, and natron. The Historical Table of the Materia Media reports crocodile oil use in Egyptian Medicine in creating the ointment with combination of "slime of the nile", frictions of crocodile fat in rheumatism, salt, alum, platters. In Africa, crocodile oil is used for ailments such as skin rashes and to promote wound healing. There is also evidence of crocodile oil being used traditionally in South Africa. South Africans consult traditional healers, who still play a role in healthcare in rural areas. Crocodile fat is mixed with the ground bark of Cryptocarya latifolia and used by the Zulu people to treat chest ailments. Crocodile oil was also used by Indian Ayurveda medicine in the nineteenth century for treatment of burns.
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.